Starjemza FDA Approval History
FDA Approved: Yes (First approved May 22, 2025)
Brand name: Starjemza
Generic name: ustekinumab-hmny
Dosage form: Injection
Company: Bio-Thera Solutions, Ltd.
Starjemza (ustekinumab-hmny) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Development timeline for Starjemza
| Date | Article |
|---|---|
| May 27, 2025 | Approval FDA Approves Starjemza (ustekinumab-hmny), a Biosimilar to Stelara |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.